24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients

E. Randy Craven,Thomas R Walters,William C. Christie,Douglas G. Day,Richard A. Lewis,Margot L. Goodkin,Michelle Y. Chen,Veronica Wangsadipura,Michael R. Robinson,Marina Bejanian

24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients

2019

E. Randy Craven
Thomas R Walters
William C. Christie
Douglas G. Day
Richard A. Lewis
Margot L. Goodkin
Michelle Y. Chen
Veronica Wangsadipura
Michael R. Robinson
Marina Bejanian

Objective The objective of this study was to evaluate the safety and intraocular pressure (IOP)-lowering effects over 24 months of biodegradable bimatoprost sustained-release implant (Bimatoprost SR) administration versus topical bimatoprost 0.03% in patients with open-angle glaucoma (OAG).

Keywords:

Anesthesia
Bimatoprost
Clinical trial
Diabetes mellitus
Glaucoma
Pharmacotherapy
Medicine
Intraocular pressure
Implant
Prostaglandin analog
Adverse effect
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations